I could write a media piece called:
After decades of research and dozens of clinical trials, Bistantrene still stuck in research phase. About to start yet another trial in the very crowded AML space.
I'm sure you would agree that that doesn't necessarily mean there is no bright future for Bisantrene.
Imugene are targeting large solid tumour markets with Vaxinia and OnCARlytics - success and huge profits does not require 100% market share in all those tumour types.
From the Professor..., page-127
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |